Study of Pembrolizumab and Olaparib in Bile Duct Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Olaparib
Related studies linked through entity extraction aliases.
DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
NUVOLA TRIAL Open-label Multicentre Study
- Status
- UNKNOWN
- Phase
- PHASE2
A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.
- Status
- WITHDRAWN
- Phase
- PHASE2
Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours
- Status
- COMPLETED
- Phase
- PHASE1
Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
- Status
- COMPLETED
- Phase
- PHASE2
Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients
- Status
- COMPLETED
- Phase
- N/A
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
- Status
- COMPLETED
- Phase
- PHASE2
ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
- Status
- RECRUITING
- Phase
- EARLY_PHASE1